Putting "Buy" in Biotech: Investors Flock to a Sector Shunned in the 90's
Washington Post 2000 February 25; p. E1, E4
Showing items related by title, author, creator and subject.
Cracking the Code: A Bold Business Experiment Is Unfolding at Celera Genomics, Where Scientists Face a Herculean Task: Unravel the 3.5 Billion Letters of the Human Genetic Code. The Big Question for Investors: Can the Maryland Biotech Company Earn a Profit on Its Research? Gillis, Justin (1999-09-27)